Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1036921 | 1.00 | DPP4 (0.50) | DPP4F2CYP2D6HTR2ATAAR1 | |
| SCHEMBL255230 | 1.00 | DPP4 (0.50) | DPP4F2CYP2D6HTR2ATAAR1 | |
| Hydrochloric Acid SCHEMBL28664928 | 0.97 | DPP4 (0.48) | DPP4F2CYP2D6HTR2ATAAR1 | |
| Ammonia Solution, Strong SCHEMBL28379624 | 0.97 | DPP4 (0.48) | DPP4F2CYP2D6HTR2ATAAR1 | |
| Hydrochloric Acid SCHEMBL20900097 | 0.97 | DPP4 (0.48) | DPP4F2CYP2D6HTR2ATAAR1 | |
| SCHEMBL5534886 | 0.86 | CHRNB2 (0.47) | DPP4TAAR1 | |
| Hydrochloric Acid SCHEMBL13738816 | 0.83 | TYR (0.33) | — | |
| Hydrochloric Acid SCHEMBL3388587 | 0.77 | DRD1 (0.32) | — | |
| Hydrochloric Acid SCHEMBL2035158 | 0.77 | DRD1 (0.32) | — | |
| SCHEMBL21335077 | 0.77 | DPP4 (0.42) | DPP4F2CYP2D6HTR2ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1051547-C | Beta-lactams derivative and its prep. and use | HOFFMANN LA ROCHE (CH) | 2000-04-19 | — | — | CN | claimed |
| CN-1132752-A | Beta-lactam derivatives, process for their preparation and their use | HOFFMANN LA ROCHE (CH) | 1996-10-09 | — | — | CN | claimed |
| WO-2014204895-A1 | TREATMENT OF OBESITY AND PULMONARY ARTERIAL HYPERTENSION | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014141181-A1 | PROCESS FOR PREPARING PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
| US-20130041156-A1 | AZAPEPTIDE DERIVATIVES | HARBESON SCOTT L (US) | 2013-02-14 | — | — | US | disclosed |
| US-20120244122-A1 | Peptides for the Treatment of HCV Infections | CONCERT PHARMACEUTICALS, INC. | 2012-09-27 | — | — | US | disclosed |
| EP-2049116-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20120009637-A1 | Nitrilases, Nucleic Acids Encoding Them and Methods For Making and Using Them | VERENIUM CORPORATION (US) | 2012-01-12 | — | — | US | disclosed |
| EP-2295413-A1 | Indazole compounds useful as protein kinase inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-2295412-A1 | Indazole compounds useful as protein kinase inhibitors | Vertex Pharmaceuticals Incorporated (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-7790747-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100061960-A1 | Amido Anti-Viral Compounds, Compositions, And Methods Of Use | SCHMITZ FRANZ ULRICH | 2010-03-11 | — | — | US | disclosed |
| WO-2009102694-A1 | HETEROCYCLIC DERIVATIVES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090175824-A1 | Peptides for the treatment of HCV infections | CONCERT PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090099205-A1 | Chemokine receptor binding compounds | GENZYME CORPORATION | 2009-04-16 | — | — | US | disclosed |
| US-20090036357-A1 | Azapeptide derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| US-5494666-A | BETA-LACTAMASE INHIBITORS, ANTIBACTERIALS | HOFFMANN-LA ROCHE INC. (US) | 1996-02-27 | — | — | US | disclosed |
| US-5464617-A | 1H-2,6a-diazacyclobut(cd)indene-6-carboxylic acid derivatives, antibiotics | HOFFMANN-LA ROCHE INC. (US) | 1995-11-07 | — | — | US | disclosed |
| EP-0671401-A1 | Beta lactames | F. HOFFMANN-LA ROCHE AG (CH) | 1995-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130041156-A1 | AZAPEPTIDE DERIVATIVES | SAMHD1, ENTPD5, DNPEP | DPP4 11/4885F2 4751/4885CYP2D6 738/4885 |
| US-20090036357-A1 | Azapeptide derivatives | SAMHD1, ENTPD5, DNPEP | DPP4 11/4885F2 4751/4885CYP2D6 738/4885 |
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | CCR5, CXCR3, CCL5 | DPP4 2004/4885F2 4488/4885CYP2D6 3964/4885 |
| US-20090175824-A1 | Peptides for the treatment of HCV infections | DPP4, ZC3HAV1, CTSC | DPP4 1/4885F2 3000/4885CYP2D6 3182/4885 |
| US-20100061960-A1 | Amido Anti-Viral Compounds, Compositions, And Methods Of Use | HAVCR2, OAT, MAVS | DPP4 167/4885F2 607/4885CYP2D6 3338/4885 |
| US-20120244122-A1 | Peptides for the Treatment of HCV Infections | HAVCR2, VIP, PEPD | DPP4 11/4885F2 2311/4885CYP2D6 3084/4885 |
| US-20120009637-A1 | Nitrilases, Nucleic Acids Encoding Them and Methods For Making and Using Them | RNGTT, NSUN2, NSUN3 | DPP4 2633/4885F2 4797/4885CYP2D6 2258/4885 |
| US-20090099205-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | DPP4 2004/4885F2 4488/4885CYP2D6 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.